Concepedia

Publication | Open Access

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

DOIFull Paper Access

78

Citations

26

References

2015

Year

Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, David Linsenmayer, Maureen M. Hattersley, Aaron Smith, Joanne Wilson,
Clinical Cancer Research

Abstract

Data presented provide the first report testing therapeutics in preclinical in vivo models of PRCC and support the clinical development of AZD6094 in this indication.

References

YearCitations

Page 1